Please login to the form below

Not currently logged in
Email:
Password:

ABPI's David Fisher defends drug pricing

ABPI commercial director, David Fisher has responded to criticism levied at the pharmaceutical industry over its pricing

The Association of the British Pharmaceutical Industry (ABPI) commercial director, David Fisher has responded to criticism levied at the pharmaceutical industry over its pricing. In a viewpoint published on the BBC website, he says that companies "are unfairly attacked".

Fisher also says that pharma risks "millions upon millions of pounds in order to find new medicines to treat people who are sick and dying and for whom there is currently no treatment. The odds of success," he points out, "are almost impossible".

He also refers to the Pharmaceutical Price Regulation Scheme (PPRS) and its remit to cap the profits that the pharma industry can make. He puts forward the argument that the price of medicines in the UK was slashed by 7 per cent in 2005, with a further 3.9 per cent reduction this year, and a 2.9 per cent decrease due in 2010, and adds that prices in the UK are amongst the lowest in Europe.

12th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...

Infographics